Impact of Empagliflozin Add-on Therapy on Quality of Life in Patients of Type 2 Diabetes Mellitus with Hypertension: A Prospective Study

Simple item page
dc.contributor.authorNajar, IAen_US
dc.contributor.authorMasoodi, SRen_US
dc.contributor.authorMir, SAen_US
dc.contributor.authorBhat, MHen_US
dc.contributor.authorPatyar, RRen_US
dc.contributor.authorPatyar, S.en_US
dc.date.accessioned2023-08-19T04:55:46Z
dc.date.available2023-08-19T04:55:46Z
dc.date.issued2022-11
dc.description.abstractBackground: Diabetes has a negative impact on patient’s quality of life (QoL). Comorbidities and polypharmacy further worsen their QoL. Thus, in addition to glycemic control, assessment of QoL is also gaining importance. Objective: The objective of this study was to evaluate QoL in patients of type 2 diabetes mellitus (T2DM) with hypertension after add?on empagliflozin to triple drug therapy (metformin, teneligliptin, and glimepiride). Materials and Methods: A prospective research was done on T2DM patients with hypertension, who visited a tertiary care referral institute’s endocrine outpatient clinic. For 3 months, empagliflozin, 25 mg once daily, was administered as an add?on treatment with metformin, teneligliptin, and glimepiride. In addition to clinical assessment, an Urdu-translated QoL instrument for Indian diabetes patients was used to conduct QoL study. The QoL outcomes prior to empagliflozin add?on were compared with those obtained at the conclusion of the 3 months of treatment. Results: Empagliflozin as an add?on therapy significantly improved various aspects of QoL like role limitation due to physical health, physical endurance, general health, symptom botherness, financial worries, emotional/mental health, and diet satisfaction (P < 0.001). It also improved glycemic and blood pressure parameters significantly. Conclusion: QoL is an essential measure with respect to patient?centered treatment approach. Empagliflozin, as an add?on medication, improved QoL, glycemic parameters and blood pressure in T2DM patients with hypertension. It can be recommended as an add?on, but more research with a larger sample size is required.en_US
dc.identifier.affiliationsPhD Scholaren_US
dc.identifier.affiliationsProfessoren_US
dc.identifier.affiliationsAssociate Professor, Department of Clinical Pharmacology, SKIMS Deemed Universityen_US
dc.identifier.affiliationsSenior Resident, Department of Endocrinology, SKIMS Deemed Universityen_US
dc.identifier.affiliationsLecturer, Department of Medicine, Government Medical College, Srinagar, Jammu and Kashmir, Indiaen_US
dc.identifier.affiliationsLecturer, Department of Technical Education and Industrial Training, Punjaben_US
dc.identifier.affiliationsProfessor, Department of Pharmacology, Lovely Professional University, Jalandharen_US
dc.identifier.citationNajar IA, Masoodi SR, Mir SA, Bhat MH, Patyar RR, Patyar S.. Impact of Empagliflozin Add-on Therapy on Quality of Life in Patients of Type 2 Diabetes Mellitus with Hypertension: A Prospective Study. Indian Journal of Public Health. 2022 Nov; 66(1): 41-44en_US
dc.identifier.issn0019-557X
dc.identifier.issn2229-7693
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223782
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume66en_US
dc.source.urihttps://doi.org/10.4103/ijph.ijph_1070_22en_US
dc.subjectEmpagliflozinen_US
dc.subjecthypertensionen_US
dc.subjectquality of life instrument in diabetesen_US
dc.subjecttype 2 diabetesen_US
dc.titleImpact of Empagliflozin Add-on Therapy on Quality of Life in Patients of Type 2 Diabetes Mellitus with Hypertension: A Prospective Studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJPH2022v66s1p41.pdf
Size:
441.62 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Public Health